According to the WHO CNS5 criteria, molecular markers such as IDH mutation status, 1p/19q codeletion, ATRX, and TP53 are essential for accurate tumor classification and prognostic stratification of gliomas. This evidence concerns the gene ATRX and central nervous system cancer.